Drug Trial Radar · NCT07297797
Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension
Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
238
Actual
Start
Jan 14, 2026
Primary completion
Dec 2026
Study completion Oct 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.
Conditions
- Mild to Moderate Hypertension
Interventions
HRS-9563 InjectionDrug
HRS-9563 Injection
sodium chloride injectionDrug
sodium chloride injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in 24-hour mean systolic blood pressure assessed by ABPM at month 6Time frame: at 6 months after initiation of administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.